Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLV3
- Development stage
- Unknown
- Lead developer
- University of Missouri-Kansas City
- Modality
- Antibody-Based Therapeutics
01
Overview
CLV3: sourced facts only. name: "Here, we use a phage display library to identify an anti-PD-L1 sdAb (CLV3) which effectively blocks the PD-1/PD-L1 interaction." [DOI:10.1158/1538-7445.am2022-600]; target: "Here, we use a phage display library to identify an anti-PD-L1 sdAb (CLV3) which effectively blocks the PD-1/PD-L1 interaction." [DOI:10.1158/1538-7445.am2022-600]; developer: "1University of Missouri-Kansas City, Kansas City, MO." [DOI:10.1158/1538-7445.am2022-600]; modality: "Single-domain antibody fragment (sdAb) is an antibody fragment composed of a single variable domain of the heavy chain." [DOI:10.1158/1538-7445.am2022-600]
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on CLV3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLV3.